



## Call for Abstracts

Abstract submission opens: **02 November 2017**

Deadline Abstract submission: **28 February 2018**

Abstracts can only be submitted online.

### Abstract Regulations

---

With the submission of an abstract to EACR25, the first author (presenting author):

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the congress.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published. Submitted abstracts **cannot be withdrawn after 11 April 2018**.

### Abstract Format

---

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
- Abstracts should be organised under the headings:
  - Introduction
  - Material and method
  - Results and discussion
  - Conclusion

- The online abstract submission procedure will **not** accept abstracts that exceed 2,500 characters (body of the abstract)
- Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
- Supplementary data or appendices will not be accepted.
- Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by email from the EACR25 Congress Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process, please contact our support team via: [EACR25@covr.be](mailto:EACR25@covr.be)

## Abstract Selection Process

---

The Scientific Committee will make the selection of abstracts for oral and poster presentations by late March 2018. The presenting author will receive an email with the result of the review and the Scientific Committee’s decision on the abstract.

If a selected author cannot attend, the presenting author should assign a replacement.

The following presentation formats are applicable for EACR25:

1. Oral presentation: the abstract is selected for oral presentation in a main programme symposium
2. Poster: abstracts that have been selected for presentation in poster format. Posters are grouped by topic and will be displayed during specific Poster Sessions. A formal Poster Defence Session will be scheduled.
3. Poster in the Spotlight session: in addition to a poster presentation as above a mini oral presentation is given at a set time in the dedicated venue within the Poster Area.

**Please note that if the abstract is accepted for oral or poster presentation, the abstract will only be published in the Congress Proceedings if one of the authors is a registered participant to EACR25 and full payment has been received by the advised deadline.**

## Abstract Submission

---

### Abstract submission procedure

Abstracts must be submitted online, from 02 November 2017 to 28 February 2018, via the EACR25 website.

Please follow the instructions on the screen.

Please note:

- When finished with the online submission, please click the “FINAL SUBMISSION” button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click “SAVE AND CLOSE”. This button allows you to update your abstract before final submission.
- After clicking “SAVE AND CLOSE”, your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click “FINAL SUBMISSION”. If you have not FINAL SUBMITTED your abstract by the **deadline of 28 February 2018** your abstract can not be accepted.
- Within 24 hours of submission, only the presenting author will receive a confirmation by email. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
- If you do not receive any confirmation, please contact [eacr25@covr.be](mailto:eacr25@covr.be) within one week following the submission of the abstract.
- Submitting an abstract for EACR25 does not constitute registration for the congress. Abstract presenters must register to attend EACR25 by following the instructions for registration on the EACR25 website.

For questions regarding the online submission process, please contact: [eacr25@covr.be](mailto:eacr25@covr.be)

Only abstracts submitted online can be accepted. Abstracts submitted on paper or as email attachment will unfortunately **not** be considered.

## Topics for Abstract Submission

---

### 1. **CANCER CELL BIOLOGY**

- Cell Proliferation/cell cycle
- Cell Death / Autophagy
- Oncogenes and Tumour Suppressor Genes
- Metastases and EMT
- Aging and Cancer
- Senescence
- Cancer Cell Metabolism
- Cancer Initiating Cells / Cancer Stem Cells

### 2. **TUMOUR BIOLOGY**

- Animal models of cancer
- Genetic instability
- Tumour Progression: Invasion and Metastasis
- Tumour Microenvironment
- Tumour Angiogenesis
- Tumour Inflammation
- Tumour heterogeneity/ evolution
- RNA biology in cancer (splicing, noncoding RNAs, RNA modifications)

### 3. **CANCER GENOMICS, EPIGENETICS and GENOMIC INSTABILITY**

- Genomic Alterations in Cancer
- Functional Genomics
- Epigenetic mechanisms
- Deep sequencing

### 4. **SIGNALING PATHWAYS**

- Receptors and Signal Transduction
- Gene Expression, Transcriptional Regulation
- Systems biology
- Computational models of biological systems
- Omics technologies

### 5. **CARCINOGENESIS**

- Mutagenesis, Carcinogen Metabolism
- Promotion and Progression
- DNA Damage and Repair
- Viral Oncogenesis

### 6. **TRANSLATIONAL RESEARCH**

- Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment

- Molecular pathology
- Biomarkers
- imaging
- Prognostic value of oncogenomics
- Clinical Phase I/II trials with targeted drugs and novel agents
- Bioinformatics in therapies and clinical trials
- Infrastructures (biobanks, databases, genomic resources, others)

## **7. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS**

- Drug Discovery / Drug Design
- Novel Targets, Delivery Systems
- Mechanisms of Drug Action, Drug Profiling
- Drug Resistance
- Novel Approaches to Diagnosis of Cancer
- New Therapies
- Companion diagnostics
- Personalised medicine

## **8. TUMOUR IMMUNOLOGY**

- Tumour Immunology
- Immune Suppression and Escape
- Tumour antigens and immune effectors
- Immunotherapy and Cancer Vaccines

## **9. RADIOBIOLOGY / RADIATION ONCOLOGY**

- Tumour Cell Sensitisation to Radiotherapy
- Radiation-activated Signaling Pathways
- Cell Cycle and Apoptosis in Radiation Responses
- Radiation Oncology; Preclinical and Clinical
- Translational radiation research

## **10. MOLECULAR AND GENETIC EPIDEMIOLOGY**

- Risk Factors
- Risk Assessment
- Susceptibility Genes
- Genotype / Phenotype Correlations
- Genetic Polymorphisms and Cancer Susceptibility
- Epidemiology

## **11. PREVENTION and EARLY DETECTION**

- Preclinical Prevention Studies, Markers and Prevention
- Clinical Prevention Studies
- Vaccination Against Cancer

## 12. OTHER

**If you indicate “preference for Oral presentation” you will also have to also mark which of the below mentioned Symposia is best suited for your abstract:**

1. DNA Damage
2. Epigenetics
3. Immunogenomics
4. Invasion and Metastasis
5. Late Breaking Therapies
6. Mechanisms of Resistance to Tumour Therapy
7. Microbiome and Cancer
8. Models for Immunotherapy
9. Paediatric Cancers
10. Response and Resistance in Cancer Immunotherapy
11. Stem Cells
12. Systems Medicine Making Sense of Big Data
13. The RAS Pathway and Cancer
14. Tracking Cancer in the Blood
15. Tumour Heterogeneity and Evolution
16. Tumour Metabolism
17. Tumour Microenvironment